ADJunctive Ulinastatin in Sepsis Treatment in China (ADJUST study): Study protocol for a randomized controlled trial

Trials

Volumn 19, Issue 1, 2018, Pages

  Jiang, Wei ^a   Yu, Xiangyou ^b   Sun, Tongwen ^c   Chai, Yanfen ^d   Chang, Ping ^e   Chen, Zhongqing ^e   Pan, Jingye ^f   Peng, Zhiyong ^g   Wang, Ruilan ^h   Wang, Xiaozhi ⁱ   Xu, Yuan ^j   Yu, Li ^k   Zheng, Qingshan ^l   Du, Bin ^a  

^a PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^b XINJIANG MEDICAL UNIVERSITY   (China)

^c THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIVERSITY   (China)

^d TIANJIN MEDICAL UNIVERSITY   (China)

^e SOUTHERN MEDICAL UNIVERSITY   (China)

^f THE FIRST AFFILIATED HOSPITAL OF WENZHOU MEDICAL UNIVERSITY   (China)

^g ZHONGNAN HOSPITAL OF WUHAN UNIVERSITY   (China)

^h SHANGHAI FIRST PEOPLE S HOSPITAL   (China)

ⁱ BINZHOU MEDICAL UNIVERSITY   (China)

^j BEIJING TSINGHUA CHANGGUNG HOSPITAL   (China)

^k HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^l SHANGHAI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

more..

Author keywords

Mortality; Randomized controlled trial; Safety; Sepsis; Septic shock; Ulinastatin

Indexed keywords

ASPARTATE AMINOTRANSFERASE; C REACTIVE PROTEIN; INTERLEUKIN 10; INTERLEUKIN 6; LACTIC ACID; PLACEBO; TUMOR NECROSIS FACTOR; ULINASTATIN; ANTIINFLAMMATORY AGENT; GLYCOPROTEIN;

ALL CAUSE MORTALITY; ANAPHYLAXIS; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; EOSINOPHILIA; HOSPITAL DISCHARGE; HOSPITAL MORTALITY; HOT FLUSH; HUMAN; INJECTION SITE PAIN; INTENSIVE CARE UNIT; INTENSIVE CARE UNIT MORTALITY; LACTATE BLOOD LEVEL; LENGTH OF STAY; LIFE SUSTAINING TREATMENT; MORTALITY; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; PROSPECTIVE STUDY; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; SEPSIS; SEQUENTIAL ORGAN FAILURE ASSESSMENT SCORE; SIDE EFFECT; VOMITING; ADOLESCENT; ADULT; AGED; CHINA; FEMALE; MALE; MIDDLE AGED; MULTICENTER STUDY (TOPIC); TIME FACTOR; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS; CHINA; DOUBLE-BLIND METHOD; FEMALE; GLYCOPROTEINS; HUMANS; MALE; MIDDLE AGED; MULTICENTER STUDIES AS TOPIC; PROSPECTIVE STUDIES; SEPSIS; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 85042420359     PISSN: None     EISSN: 17456215     Source Type: Journal    
DOI: 10.1186/s13063-018-2513-y     Document Type: Article

References (53)

1. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med. 2001;29(7):1303-10.
2. Cohen J, Vincent J-L, Adhikari NKJ, Machado FR, Angus DC, Calandra T, et al. Sepsis: a roadmap for future research. Lancet Infect Dis. 2015;15(5):581-614.
3. Fleischmann C, Scherag A, Adhikari NKJ, Hartog CS, Tsaganos T, Schlattmann P, et al. Assessment of global incidence and mortality of hospital-treated sepsis. Am J Resp Crit Care Med. 2016;193(3):259-72.
4. Zhou J, Tian H, Du X, Xi X, An Y, Duan M, et al. Population-based epidemiology of sepsis in a subdistrict of Beijing. Crit Care Med. 2017;45(7):1168-76.
5. Angus DC, van der Poll T. Severe sepsis and septic shock. N Engl J Med. 2013;369(9):840-51.
6. Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016;315(8):801-10.
7. Hotchkiss RS, Monneret G, Payen D. Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy. Nat Rev Immunol. 2013;13(12):862-74.
8. Christaki E, Anyfanti P, Opal SM. Immunomodulatory therapy for sepsis: an update. Expert Rev Anti-Infect Ther. 2011;9(11):1013-33.
9. Opal S, Laterre PF, Abraham E, Francois B, Wittebole X, Lowry S, et al. Recombinant human platelet-activating factor acetylhydrolase for treatment of severe sepsis: results of a phase III, multicenter, randomized, double-blind, placebo-controlled, clinical trial. Crit Care Med. 2004;32(2):332-41.
10. Levin M, Quint PA, Goldstein B, Barton P, Bradley JS, Shemie SD, et al. Recombinant bactericidal/permeability-increasing protein (rBPI21) as adjunctive treatment for children with severe meningococcal sepsis: a randomised trial. Lancet. 2000;356(9234):961-7.
11. Sharony R, Yu PJ, Park J, Galloway AC, Mignatti P, Pintucci G. Protein targets of inflammatory serine proteases and cardiovascular disease. J Inflamm (Lond). 2010;7:45.
12. Shigetomi H, Onogi A, Kajiwara H, Yoshida S, Furukawa N, Haruta S, et al. Anti-inflammatory actions of serine protease inhibitors containing the Kunitz domain. Inflamm Res. 2010;59(9):679-87.
13. Inoue K-i, Takano H, Yanagisawa R, Yoshikawa T. Protective effects of urinary trypsin inhibitor on systemic inflammatory response induced by lipopolysaccharide. J Clin Biochem Nutr. 2008;43(3):139-42.
14. Wakahara K, Kobayashi H, Yagyu T, Matsuzaki H, Kondo T, Kurita N, et al. Bikunin suppresses lipopolysaccharide-induced lethality through down-regulation of tumor necrosis factor-alpha and interleukin-1 beta in macrophages. J Infect Dis. 2005;191(6):930-8.
15. Ueki M, Taie S, Chujo K, Asaga T, Iwanaga Y, Ono J, et al. Urinary trypsin inhibitor reduces inflammatory response in kidney induced by lipopolysaccharide. J Biosci Bioeng. 2007;104(4):315-20.
16. Tanaka R, Fujita M, Tsuruta R, Fujimoto K, Aki HS, Kumagai K, et al. Urinary trypsin inhibitor suppresses excessive generation of superoxide anion radical, systemic inflammation, oxidative stress, and endothelial injury in endotoxemic rats. Inflamm Res. 2010;59(8):597-606.
17. Huang N, Wang F, Wang Y, Hou J, Li J, Deng X. Ulinastatin improves survival of septic mice by suppressing inflammatory response and lymphocyte apoptosis. J Surg Res. 2013;182(2):296-302.
18. Cao YZ, Tu YY, Chen X, Wang BL, Zhong YX, Liu MH. Protective effect of ulinastatin against murine models of sepsis: inhibition of TNF-alpha and IL-6 and augmentation of IL-10 and IL-13. Exp Toxicol Pathol. 2012;64(6):543-7.
19. Moon SW, Lee SW, Hong YS, Park DW, Jang IJ, Yoon YH, et al. The effects of urinary trypsin inhibitor on the outcomes of severe sepsis and septic shock patients. J Korean Soc. Emerg Med. 2009;20(1):80-5.
20. Chen S, Chen X, Lai J, Yao Z. Clinical effect of ulinastatin in the treatment of septic shock. Dang Dai Yi Xue. 2012;18(18):148-50.
21. Liu D, Yu Z, Yin J, Chen Y, Zhang H, Xin F, et al. Effect of ulinastatin combined with thymosin alpha1 on sepsis: a systematic review and meta-analysis of Chinese and Indian patients. J Crit Care. 2017;39:259-66.
22. Karnad DR, Bhadade R, Verma PK, Moulick ND, Daga MK, Chafekar ND, et al. Intravenous administration of ulinastatin (human urinary trypsin inhibitor) in severe sepsis: a multicenter randomized controlled study. Intensive Care Med. 2014;40(6):830-8.
23. Zhou J, Qian C, Zhao M, Yu X, Kang Y, Ma X, et al. Epidemiology and outcome of severe sepsis and septic shock in intensive care units in mainland China. PLoS One. 2014;9(9):e107181.
24. Machado FRCA, Bozza FA, Ferreira EM, Angotti Carrara FS, Sousa JL, et al. The epidemiology of sepsis in Brazilian intensive care units (the Sepsis PREvalence Assessment Database, SPREAD): an observational study. Lancet Infect Dis. 2017;17(11):1180-9.
25. Vincent JL, Moreno R, Takala J, Willatts S, De Mendonca ABH, Reinhart CK, et al. The SOFA (sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med. 1996;22(7):707-10.
26. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2013;128(16):e240-327.
27. Cholongitas E, Papatheodoridis GV, Vangeli M, Terreni N, Patch D, Burroughs AK. Systematic review: the model for end-stage liver disease-should it replace Child-Pugh's classification for assessing prognosis in cirrhosis? Aliment Pharm Therap. 2005;22(11-12):1079-89.
28. Liver Failure and Artificial Liver Group CSoID. Chinese Medical Association; Severe Liver Diseases and Artificial Liver Group, Chinese Society of Hepatology, Chinese Medical Association. Diagnostic and treatment guidelines for liver failure. Chin J Hepatol. 2013;21(3):177-83.
29. Pappas PG, Kauffman CA, Andes DR, Clancy CJ, Marr KA, Ostrosky-Zeichner L, et al. Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;62(4):e1-50.
30. Patterson TF, Thompson GR 3rd, Denning DW, Fishman JA, Hadley S, Herbrecht R, et al. Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;63(4):e1-e60.
31. Dosanjh DPS, Hinks TSC, Innes JA, Deeks JJ, Pasvol G, Hackforth S, et al. Improved diagnostic evaluation of suspected tuberculosis. Ann Intern Med. 2008;148(5):325-36.
32. Pocock SJ, Simon R. Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics. 1975;31(1):103-15.
33. Brown S, Thorpe H, Hawkins K, Brown J. Minimization-reducing predictability for multi-centre trials whilst retaining balance within centre. Stat Med. 2005;24(24):3715-27.
34. Rhodes A, Evans LE, Alhazzani W, Levy MM, Antonelli M, Ferrer R, et al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016. Intensive Care Med. 2017;43(3):304-77.
35. Shao Y, Zhang L, Deng L, Yao H. Clinical study on effects of ulinastatin on patients with systemic inflammatory response syndrome. Chin. Crit Care Med. 2005;17(4):228-30.
36. Wu C, Xiao F, Gan L, Xu Q, Yu X, Shi L, et al. Tolerance of ulinastatin in healthy volunteers. Chin J Clin Pharmacol Ther. 2007;12(1):103-6.
37. Liu Y, Wang Q, Zhan H, Jiang D, Wang Y, Li J, et al. Tolerance study of ulinastatin injection in Chinese healthy volunteers. Chin J Clin Pharmacol. 2015;31(21):2111-3.
38. Liu Y, Wu X. Effect of ulinastatin on serum levels of tumor necrosis factor-alpha, P-selectin, and thrombin-antithrombin complex in young rats with sepsis. Chin J Contemp Pediatr. 2017;19(2):237-41.
39. Liang Y. Clinical efficacy of various doses of ulinastatin in patients with severe sepsis. He Bei Yi Yao. 2013;35(14):2116-7.
40. Mahoney FI, Barthel DW. Functional evaluation: the Barthel Index. Md State Med J. 1965;14:61-5.
41. Package insert of ulinastatin for injection. Available from: https://wenku.baidu.com/view/b4111b09bb68a98271fefaf4.html. Accessed 23 Jan 2018.
42. Li J, Lai J, Jiang Y, Yao Z, Chen X, Chen S. Study of ulinastatin against gastrointestinal complications in patients with septic shock. Xian Dai Yi Xue. 2010;38(3):263-5.
43. Li J, Lai J, Liu C, Yao Z, Chen S, Chen X, et al. Clinical study of ulinastatin on lung injury in patients with septic shock. Xian Dai Yi Xue. 2011;39(1):41-4.
44. Wang L, Zhong H, Zhang J. Clinical effects of ulinastatin in 90 patients with septic shock. Zhong Guo Bao Jian Ying Yang. 2013;1(1):222.
45. Feng L, Zhou Q. Meta-analysis of the efficacy of the septic shock by therapy of ulinastatin. Chin J Clinicians (electronic edition). 2013;7(9):3952-6.
46. The ARDS Definition Task Force. Acute respiratory distress syndrome: the Berlin Definition. JAMA. 2012;307(23):2526-33.
47. Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Chest. 1992;101(6):1644-55.
48. Association EMBoCMD. Expert consensus on acute circulatory failure: clinical practice of Chinese emergency physicians. Chin J Emerg Med. 2016;25(2):143-9.
49. Lim YP, Bendelja K, Opal SM, Siryaporn E, Hixson DC, Palardy JE. Correlation between mortality and the levels of inter-alpha inhibitors in the plasma of patients with severe sepsis. J Infect Dis. 2003;188(6):919-26.
50. Linder A, Russell JA. An exciting candidate therapy for sepsis: ulinastatin, a urinary protease inhibitor. Intensive Care Med. 2014;40(8):1164-7.
51. Seymour CW, Liu VX, Iwashyna TJ, Brunkhorst FM, Rea TD, Scherag A, et al. Assessment of clinical criteria for sepsis: for the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016;315(8):762-74.
52. Raith EP, Udy AA, Bailey M, McGloughlin S, MacIsaac C, Bellomo R, et al. Prognostic Accuracy of the SOFA score, SIRS criteria, and qSOFA score for in-hospital mortality among adults with suspected infection admitted to the intensive care unit. JAMA. 2017;317(3):290-300.
53. Chatterjee S, Bhattacharya M, Todi SK. Epidemiology of adult-population sepsis in India: a single center 5 year experience. Indian J Crit Care Med. 2017;21(9):573-7.